This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells
Scientific Reports Open Access 03 February 2021
-
Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification
Cell Death & Disease Open Access 06 August 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Eng J Med 2000; 343: 1910–1916.
Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR . Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002; 100: 1404–1409.
Stilgenbauer S, Bullinger L, Lichter P, Dohner H, the German CLL Study Group (GCLLSG). Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993–1007.
Carter A, Lin K, Sherrington PD, Pettitt AR . Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004; 127: 425–428.
Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T . p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814–822.
Lin K, Manocha S, Harris RJ, Matrai Z, Sherrington PD, Pettitt AR . High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3–21 gene segment. Blood 2003; 102: 1145–1146.
Thornton PD, Gruszka-Westwood AM, Hamoudi RA, Atkinson S, Kaczmarek P, Morilla RM et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 2004; 5: 47–54.
Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P . Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 748–753.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carter, A., Lin, K., Sherrington, P. et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia 20, 737–740 (2006). https://doi.org/10.1038/sj.leu.2404120
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404120
This article is cited by
-
Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells
Scientific Reports (2021)
-
Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification
Cell Death & Disease (2015)
-
A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL
Leukemia (2008)
-
Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells
Oncogene (2008)
-
The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia
Leukemia (2007)